Company intelligence / Profile preview

Quimatryx

San Sebastián, Gipuzkoa, Spain

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Quimatryx is a clinical-stage biotechnology company based in Spain that specializes in the development of epigenetic-based therapies. The company focuses on the discovery and development of small molecule inhibitors targeting histone deacetylases (HDACs), with a particular emphasis on selective HDAC6 and HDAC11 inhibitors. Its lead candidate, QTX125, is a potent and selective HDAC6 inhibitor currently being evaluated in clinical trials for the treatment of hematological malignancies such as multiple myeloma and lymphoma. Beyond oncology, Quimatryx is exploring the potential of its epigenetic modulators in neurodegenerative and inflammatory diseases.

Therapeutic areas: ImmunologyNeurologyOncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

QTX-153

Preclinical

Partnerships

Oncomatryx

Beyond the preview

Go deeper on Quimatryx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quimatryx.

Explore the full profile